A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

NCT04985266 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

1100

Enrollment

OTHER

Sponsor class

Conditions

ER+ Breast Cancer
HER2-negative Breast Cancer

Interventions

DRUG: Palbociclib 125Mg Tab
DRUG: Fulvestrant injection
DRUG: Tamoxifen
DRUG: Letrozole
DRUG: Exemestane
DRUG: Anastrozole

Sponsor

Royal Marsden NHS Foundation Trust

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]